Advertisement

Comment rationaliser le suivi après traitement local?

  • Tobias Klatte
  • Maxime Crepel
  • Allan J. Pantuck
Chapter
  • 331 Downloads
Part of the Oncologie pratique book series (ONCOLPRAT)

Abstrait

Les carcinomes à cellules rénales (CCR) représentent environ 3 % de ľensemble des cancers de ľadulte. Le diagnostic de CCR est porté dans le monde chez environ 200000personnes tous les ans et 100000personnes environ en meurent (1). Ľincidence du CCR a augmenté régulièrement durant les dernières décennies, principalement par le fait de la diffusion de plus en plus répandue des techniques ďimagerie abdominale, comme ľéchographie et le scanner (2).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Parkin DM, Bray F, Ferlay J et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108PubMedCrossRefGoogle Scholar
  2. 2.
    Chow WH, Devesa SS, Warren JL et al. (1999) Rising incidence of renal cell cancer in the United States. JAMA 281: 1628–31PubMedCrossRefGoogle Scholar
  3. 3.
    Zisman A, Pantuck AJ, Wieder J et al. (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20: 4559–66PubMedCrossRefGoogle Scholar
  4. 4.
    Atzpodien J, Schmitt E, Gertenbach U et al. (2005) Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92: 843–6PubMedCrossRefGoogle Scholar
  5. 5.
    Clark JI, Atkins MB, Urba WJ et al. (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21: 3133–40PubMedCrossRefGoogle Scholar
  6. 6.
    Messing EM, Manola J, Wilding G et al. (2003) Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21: 1214–22PubMedCrossRefGoogle Scholar
  7. 7.
    Pizzocaro G, Piva L, Di Fronzo G et al. (1987) Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 138: 1379–81PubMedGoogle Scholar
  8. 8.
    Pizzocaro G, Piva L, Colavita M et al. (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: A multicentric randomized study. J Clin Oncol 19: 425–31PubMedGoogle Scholar
  9. 9.
    Kavolius JP, Mastorakos DP, Pavlovich C et al. (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16: 2261–6PubMedGoogle Scholar
  10. 10.
    Tanguay S, Pisters LL, Lawrence DD et al. (1996) Therapy of locally recurrent renal cell carcinoma after nephrectomy. J Urol 155: 26–9PubMedCrossRefGoogle Scholar
  11. 11.
    Piltz S, Meimarakis G, Wichmann MW et al. (2002) Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 73: 1082–7PubMedCrossRefGoogle Scholar
  12. 12.
    Vogl UM, Zehetgruber H, Dominkus M et al. (2006) Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 95: 691–8PubMedCrossRefGoogle Scholar
  13. 13.
    Choueiri TK, Rini BI, Garcia JA et al. (2007) Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann Oncol 18: 249–55PubMedCrossRefGoogle Scholar
  14. 14.
    Eggener SE, Yossepowitch O, Pettus JA et al. (2006) Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 24: 3101–6PubMedCrossRefGoogle Scholar
  15. 15.
    Negrier S, Escudier B, Gomez F et al. (2002) Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français ďImmunotherapie. Ann Oncol 13: 1460–8PubMedCrossRefGoogle Scholar
  16. 16.
    Uzzo RG, Novick AC (2003) Surveillance strategies following surgery for renal cell carcinoma. In: Belldegrun A, Ritchie AWS, Figlin RA (eds). Renal and adrenal tumors: biology and management. Oxford University Press, New York, p 324–30Google Scholar
  17. 17.
    Ljungberg B, Alamdari FI, Rasmuson T et al. (1999) Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 84: 405–11PubMedCrossRefGoogle Scholar
  18. 18.
    Hafez KS, Novick AC, Campbell SC (1997) Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 157: 2067–70PubMedCrossRefGoogle Scholar
  19. 19.
    Levy DA, Slaton JW, Swanson DA et al. (1998) Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159: 1163–7PubMedCrossRefGoogle Scholar
  20. 20.
    Sandock DS, Seftel AD, Resnick MI (1995) A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 154: 28–31PubMedCrossRefGoogle Scholar
  21. 21.
    Shvarts O, Lam JS, Kim HL et al. (2004) Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol 172: 867–70PubMedCrossRefGoogle Scholar
  22. 22.
    Janzen NK, Kim HL, Figlin RA et al. (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30: 843–52PubMedCrossRefGoogle Scholar
  23. 23.
    Mori Y, Kondziolka D, Flickinger JC et al. (1998) Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 83: 344–53PubMedCrossRefGoogle Scholar
  24. 24.
    Hoshi S, Jokura H, Nakamura H et al. (2002) Gamma-knife radiosurgery for brain metastasis of renal cell carcinoma: results in 42 patients. Int J Urol 9: 618–25PubMedCrossRefGoogle Scholar
  25. 25.
    Rabinovitch RA, Zelefsky MJ, Gaynor JJ et al. (1994) Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 12: 206–12PubMedGoogle Scholar
  26. 26.
    Parienty RA, Richard F, Pradel J et al. (1984) Local recurrence after nephrectomy for primary renal cancer: computerized tomography recognition. J Urol 132: 246–9PubMedGoogle Scholar
  27. 27.
    Sease WC, Belis JA (1986) Computerized tomography in the early postoperative management of renal cell carcinoma. J Urol 136: 792–4PubMedGoogle Scholar
  28. 28.
    Itano NB, Blute ML, Spotts B et al. (2000) Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 164: 322–5PubMedCrossRefGoogle Scholar
  29. 29.
    Patard JJ, Shvarts O, Lam JS et al. (2004) Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 171: 2181–5PubMedCrossRefGoogle Scholar
  30. 30.
    Montie JE (1994) Follow-up after partial or total nephrectomy for renal cell carcinoma. Urol Clin North Am 21: 589–92PubMedGoogle Scholar
  31. 31.
    Stephenson AJ, Chetner MP, Rourke K et al. (2004) Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 172: 58–62PubMedCrossRefGoogle Scholar
  32. 32.
    Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163: 408–17PubMedCrossRefGoogle Scholar
  33. 33.
    Lam JS, Shvarts O, Leppert JT et al. (2005) Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 174: 466–72PubMedCrossRefGoogle Scholar
  34. 34.
    Antonelli A, Cozzoli A, Zani D et al. (2007) The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 99: 296–300PubMedCrossRefGoogle Scholar
  35. 35.
    Gill IS, Remer EM, Hasan WA et al. (2005) Renal cryoablation: outcome at 3 years. J Urol 173: 1903–7PubMedCrossRefGoogle Scholar
  36. 36.
    Silverman SG, Tuncali K, van Sonnenberg E et al. (2005) Renal tumors: MR imaging-guided percutaneous cryotherapy-initial experience in 23 patients. Radiology 236: 716–24PubMedCrossRefGoogle Scholar
  37. 37.
    Bolte SL, Ankem MK, Moon TD et al. (2006) Magnetic resonance imaging findings after laparoscopic renal cryoablation. Urology 67: 485–9PubMedCrossRefGoogle Scholar
  38. 38.
    Gervais DA, McGovern FJ, Arellano RS et al. (2005) Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 185: 64–71PubMedGoogle Scholar
  39. 39.
    McDougal WS (2007) Radiofrequency ablation of renal cell carcinoma. BJU Int 99: 1271–2PubMedCrossRefGoogle Scholar
  40. 40.
    Shvarts O, Seligson D, Lam J et al. (2005) p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol 173: 725–8PubMedCrossRefGoogle Scholar
  41. 41.
    Skolarikos A, Alivizatos G, Laguna P et al. (2007) A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur Urol 51: 1490–501PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2008

Authors and Affiliations

  • Tobias Klatte
    • 1
  • Maxime Crepel
    • 2
    • 3
  • Allan J. Pantuck
    • 1
  1. 1.Department of Urology David Geffen School of Medicine at UCLAUniversity of California-Los AngelesLos AngelesÉtats-Unis
  2. 2.Service ďurologieCHU PontchaillouRennes cedex 9France
  3. 3.Université de RennesRennesFrance

Personalised recommendations